XNAS · Healthcare · Biotechnology
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.10 | -0.06 | +40.00% | $14.4M | ✅ Beat | +3.40% | +48.98% | — |
| 2026-03-04 | Q4 2025 | -0.08 | -0.11 | -37.50% | $8.4M | ❌ Miss | -3.31% | +8.01% | -14.92% |
| 2025-11-04 |
| Q3 2025 |
| -0.14 |
| -0.14 |
| +0.00% |
| $2.2M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.15 | -0.15 | +0.00% | $3.9M | ➖ Inline | -0.52% | +6.22% | -11.40% |
| 2025-05-08 | Q1 2025 | -0.17 | -0.17 | +0.00% | $4.2M | ➖ Inline | — | — | — |
| 2025-03-18 | Q4 2024 | -0.10 | -0.12 | -20.00% | $10.8M | ❌ Miss | — | — | — |
| 2024-11-12 | Q3 2024 | -0.14 | -0.16 | -14.29% | $4.2M | ❌ Miss | — | — | — |
| 2024-08-08 | Q2 2024 | -0.17 | -0.13 | +23.53% | $7.6M | ✅ Beat | — | — | — |
Showing last 8 quarters.